🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple Sclerosis

Recruitingn/aAges 18 Years - 65 YearsAllAfyonkarahisar Health Sciences University
NCT07736482 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This cross-sectional observational study aims to investigate the relationship between obstacle crossing performance under single-task and dual-task conditions and the levels of fatigue and disability in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS). Walking performance will be assessed under standard walking and obstacle crossing conditions with and without a concurrent cognitive task. The study will examine how increased task complexity affects walking performance and its association with fatigue, disability, cognition, and functional mobility.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 18 and 65 years. * Diagnosis of Multiple Sclerosis according to the 2017 McDonald criteria. * Diagnosis of Relapsing-Remitting Multiple Sclerosis. * Expanded Disability Status Scale (EDSS) score between 0 and 6. * Clinically stable disease during the previous 6 months. * Montreal Cognitive Assessment (MoCA) score of 26 or higher. * Able to speak and understand Turkish. * Able to provide written informed consent. Exclusion Criteria: * Multiple sclerosis relapse within the previous month. * Physician-diagnosed psychiatric disorder. * Neurological, orthopedic, cardiac, or pulmonary disease other than Multiple Sclerosis that could interfere with study assessments. * Montreal Cognitive Assessment (MoCA) score below 26.
💊

What it tests

  • Not listed
📍

Where

1 site
Afyonkarahisar Health Sciences University
Afyonkarahisar, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy